Literature DB >> 748787

Adjuvant immunotherapy in superficial bladder cancer.

A Morales.   

Abstract

The use of BCG as an intracavitary form of immunotherapy in human bladder cancers is discussed. The result of a clinical trial in which BCG is administered in the treatment of human bladder cancers is reported. Possible uses of this tumor model in the study of immunotherapy employing BCG are suggested.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 748787

Source DB:  PubMed          Journal:  Natl Cancer Inst Monogr        ISSN： 0083-1921


  5 in total

Review 1.  Therapy of bladder cancer.

Authors:  K H Bichler; S Halim
Journal:  Int Urol Nephrol       Date:  1987       Impact factor: 2.370

2.  Adjuvant Bestatin immunotherapy in patients with transitional cell carcinoma of the bladder. Clinical results of a randomized trial.

Authors:  H Blomgren; I Näslund; P L Esposti; L Johansen; O Aaskoven
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

3.  Combined therapeutic effects of an immunomodulator, PSK, and chemotherapy with carboquone on rat bladder carcinoma.

Authors:  D D Mickey
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 4.  Repurposing Infectious Diseases Vaccines Against Cancer.

Authors:  Liese Vandeborne; Pan Pantziarka; An M T Van Nuffel; Gauthier Bouche
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

5.  Pleural Effusion Caused by Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer.

Authors:  Tara Rachakonda; Brian Kendall; Adam M Spivak; Jonathan Boltax
Journal:  Open Forum Infect Dis       Date:  2017-06-17       Impact factor: 3.835
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.